Sarcomas | Specialty

The OncLive Sarcomas/TGCT condition center page is a comprehensive resource for clinical news and expert insights on tenosynovial giant cell tumor (TGCT), soft tissue sarcoma, gastrointestinal stromal tumor, Ewing sarcoma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in sarcomas and TGCT.

Nearly 300 Novel Agents Currently in Development for Rare Cancers

February 24th 2022

New agents for rare cancers make up approximately 35% of drugs in the pipeline for all rare diseases, according to a report from the Pharmaceutical Research and Manufacturers of America.

Investigators Explore Metformin to Prevent Cancers in Li-Fraumeni Syndrome Carriers

February 22nd 2022

Individuals with Li-Fraumeni Syndrome, a rare hereditary condition, are at increased risk for a wide spectrum of malignancies, including breast cancer and sarcomas. Investigators are working to determine whether metformin, a drug indicated for diabetes and infertility caused by polycystic ovarian syndrome, can prevent cancers in LFS carriers.

Collaborations With Orthopedic Surgeons, Interventional Radiologists Key to Novel Approaches in Metastatic Bone Cancer

February 15th 2022

R. Lor Randall, MD, discusses the importance of collaborations between orthopedic surgeons and interventional radiologists, and how they are beginning to pick up steam in the United States for patients with metastatic bone cancer.

Dr. Van Tine on the Methods Utilized in the Spearhead 1 Trial in Sarcoma Subtypes

February 10th 2022

Brian A. Van Tine, MD, PhD, discusses the methods utilized in the phase 2 Spearhead 1 trial evaluating afamitresgene autoleucel in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma.

Brachytherapy Represents a Potential Strategy in AYA Patients With Rhabdomyosarcoma

February 9th 2022

Although brachytherapy is rarely utilized as a treatment for pediatric and adolescent/young adult patients in the United States, AYA patients with rhabdomyosarcoma treated with BT had favorable survival outcomes.

Imatinib/Binimetinib Combo Shows Efficacy With Manageable Safety in Treatment-Naïve Advanced GIST

February 8th 2022

The combination of the TKI inhibitor imatinib and the MEK inhibitor binimetinib elicited encouraging responses in patients with treatment-naïve advanced gastrointestinal stromal tumors.

Afami-cel Shows Clinical Benefit in Synovial Sarcoma and Myxoid/Round Cell Liposarcoma

February 7th 2022

Brian A. Van Tine, MD, PhD, sheds light on the promise of SPEAR T-cell therapy in patients with synovial sarcoma and MRCLS, the safety and efficacy observed with afami-cel in the SPEARHEAD-1 trial, and next steps for research.

Dr. Tap on Developing Treatment Opportunities in Soft Tissue Sarcomas

February 2nd 2022

William D. Tap, MD, discusses developing treatment opportunities in soft tissue sarcomas.

FDA Grants Rare Pediatric Disease Designation to Novel Radiopharmaceutical for Osteosarcoma

February 2nd 2022

The FDA has granted a rare pediatric disease designation to the bone-targeting radiopharmaceutical, Samarium-153-DOTMP, for use as a potential therapeutic option for patients with osteosarcoma.

Gender, Racial, and Socioeconomic Status Disparities Linked With Incidence of Metastatic Bone Disease

January 26th 2022

R. Lor Randall, MD, speaks to the findings from a report that said multiple sex-related, racial/ethnic, and socioeconomic status disparities are associated with an increased incidence of metastatic bone disease originating from cancers in the prostate, renal, colon, lung, and breast.

Dr. Meyer on Standard Treatment Options in Cardiac Angiosarcoma

January 14th 2022

Christian Frederick Meyer, MD, PhD, MS, discusses standard treatment options in cardiac angiosarcoma.

Alpha DaRT Elicits Complete Responses in Malignant Skin and Soft Tissue Cancers

January 11th 2022

The diffusing alpha-emitter radiation therapy, Alpha DaRT, was found to elicit complete responses per RECIST v1.1 criteria in 10 patients with malignant skin and soft tissue cancers who are enrolled to an ongoing single-institution pilot feasibility trial.

Meyer Characterizes Current Approaches to Diagnosing, Managing, and Studying Cardiac Angiosarcoma

January 10th 2022

Dr Meyer discusses the rarity of cardiac angiosarcoma, optimizing detection strategies, surgical interventions, and chemotherapy for this patient population, and why immunotherapy has the potential to transform care for patients.

Devimistat Plus Hydroxychloroquine Shows Early Promise in Relapsed Clear Cell Sarcoma

January 7th 2022

No dose-limiting toxicities have been reported in the first cohort of patients with relapsed clear cell sarcoma who received the combination of devimistat and hydroxychloroquine in the dose-escalation portion of the ongoing phase 1/2 APOLLO 613 trial.

Dr. Randall on Preventing Early Failures With Osseointegrated Endoprostheses in Bone Sarcomas

January 6th 2022

R. Lor Randall, MD, FACS, discusses methods of preventing early failures with compressive osseointegrative endoprosthetic devices of the femur in bone sarcomas.

Olaparib/Temozolomide Shows Encouraging Efficacy, Manageable Safety in Uterine Leiomyosarcoma

January 5th 2022

In patients with advanced uterine leiomyosarcoma whose tumors harbor a BRCA-like phenotype, the combination of olaparib with temozolomide could represent a new standard of care.

FDA Grants Rare Pediatric Disease Designation for IMX-110 for Rhabdomyosarcoma

January 4th 2022

The FDA has granted a rare pediatric disease designation to IMX-110 for the treatment of rhabdomyosarcoma.

Putting the Extremely Rare Cardiac Angiosarcoma in the Spotlight

December 21st 2021

Cardiac angiosarcoma is an exceptionally rare cancer that has become national news because of the recent death of acclaimed fashion designer, Virgil Abloh. He was 41 years old when he died in November 2021, following a 2-year battle with the disease, which is an aggressive subtype of soft-tissue sarcoma.

Current Management Strategies for Desmoid Tumors Are Marked by Less Surgery, More Systemic Options

December 20th 2021

Despite their rarity, the management of desmoid tumors has been an area of significant clinical change as the field has shifted away from aggressive surgical interventions to active surveillance and systemic therapies that are less morbid for patients.

Enrollment in Histologically-Specific Trials Improves Outcomes in Soft Tissue Sarcoma

December 16th 2021

Elise Nassif, MD, discusses the evolving standard of care for patients with soft tissue sarcoma and the benefits of early phase inclusion, as well as histotype testing for this population.